Abstract:

Objective To investigate the changes of serum gastrin-releasing peptide precursor（ProGRP）,neuron-specific enolase（NSE） and cytokeratin 19 fragment（CYFRA21-1） among the patients with different stages of chronic kidney disease（CKD）. Methods Totally,196 patients with impaired renal function were classified into 4 groups according to the criteria of renal function failure stages,including renal function compensation group [59 cases,creatinine（Cr） 133-177 μmol/mL],renal function decompensation group（49 cases,Cr 178-442 μmol/mL）,renal failure group（46 cases,Cr 443-706 μmol/mL） and uremia group（42 cases,Cr≥707 μmol/mL）. Totally,100 healthy subjects were enrolled as healthy control group. Serum ProGRP,NSE,CYFRA21-1 and Cr levels were determined. Results Serum ProGRP levels in healthy control group,renal function compensation group,renal function decompensation group,renal failure group and uremia group were all increased in turn（P<0.01）. Serum NSE levels in renal function decompensation group,renal failure group and uremia group were all statistically significant（P<0.05）,and all of them were higher than those in renal function compensation group and healthy control group（P<0.05）,but there was no statistical significance between renal function compensation group and healthy control group（P>0.05）. Serum CYFRA21-1 levels in all the groups with impaired renal function were higher than those in healthy control group（P<0.05）,but there was no statistical significance among renal function decompensation group,renal failure group and uremia group（P>0.05）. Among the 3 indexes,the level of serum ProGRP was increased the most significantly. Conclusions Renal function injury can lead to the increasing of ProGRP,NSE and CYFRA21-1 in different degrees. Attention should be paid to the effect of renal function on tumor markers in clinical practice.

Key words: Gastrin-releasing peptide precursor, Neuron-specific enolase, Cytokeratin 19 fragment, Renal function injury, Chronic renal function failure